Avapritinib in advanced gastrointestinal stromal tumor: case series and review of the literature from a tertiary care center in India

The therapeutic landscape in advanced gastrointestinal stromal tumor has evolved. Avapritinib and ripretinib have now been approved by the US FDA for platelet-derived growth factor alpha D842V-mutant and refractory gastrointestinal stromal tumor patients, respectively. Here we report five patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Verma, Saurav, Reddy, Rohit, Chandrashekhara, Sheragaru Hanumanthappa, Shamim, Shamim Ahmed, Tripathy, Sarthak, Rastogi, Sameer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Science Ltd 2021
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8015663/
https://www.ncbi.nlm.nih.gov/pubmed/33815822
http://dx.doi.org/10.2144/fsoa-2020-0178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8015663/
https://www.ncbi.nlm.nih.gov/pubmed/33815822
http://dx.doi.org/10.2144/fsoa-2020-0178

Ejemplares similares